MedTrace Logo

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

NCT07069569 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-05-20

No results posted yet for this study

Summary

This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.

Conditions

Interventions

DRUG

AHB-137

AHB-137 will be injected.

DRUG

Peg-IFN

Peg-IFN will be administered .

DRUG

Hepatitis B Vaccine

Hepatitis B vaccine will be administered.

Sponsors & Collaborators

  • Ausper Biopharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jia · Beijing Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-08
Primary Completion
2027-07-15
Completion
2028-01-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07069569 on ClinicalTrials.gov